Athens, 19 February 2025: INTEGRIS Pharma, a Greek pharmaceutical company, and ALTRAZEAL LIFE SCIENCES, a US-based medical technology company, are pleased to announce the expansion of their successful collaboration. Building on their existing partnership in Greece, Cyprus, Bulgaria, and Malta, INTEGRIS Pharma has secured the exclusive distribution rights for Altrazeal^® (Transforming Powder Dressing™) in 32 additional European countries, including Germany, France, Italy, Spain, Poland, Romania, Netherlands, Belgium, Czech Republic, Portugal, Sweden, Hungary, Austria, Denmark, Finland, Slovakia, Ireland, Croatia, Lithuania, Slovenia, Latvia, Estonia, Luxembourg, Serbia, Switzerland, Ukraine, Norway, Bosnia and Herzegovina, Moldova, Albania, North Macedonia and Belarus, as well as in Turkey, Israel and Azerbaijan.

Altrazeal^® (Transforming Powder Dressing™) is a revolutionary extended-wear wound management solution suitable for use with a wide range wounds. Backed by a substantial body of clinical studies^[1], Altrazeal’s advanced formulation, makes it suitable for management of various etiologies, including traumatic wounds and burns, surgical wounds and chronic ulcers of various types, including pressure ulcers, diabetic foot ulcers, vascular ulcers, and other lower limb ulcers, as well as wounds in immunocompromised patients.

Dr. Charalampos Therianos, Chief Executive Officer of INTEGRIS Pharma, stated:
“We are thrilled to expand our partnership with Altrazeal Life Sciences. This agreement enables us to bring the ground-breaking and patented technology of Altrazeal® to the European markets. By providing healthcare professionals with an advanced solution for wound and ulcer management, we are committed to improving patient care and enhancing the quality of life for thousands of individuals.”

Ms. Vaidehi Shah, Chief Executive Officer of Altrazeal Life Sciences, commented:
“Expanding our partnership with INTEGRIS Pharma marks a significant step toward establishing Altrazeal® as a global standard in wound care. Their dedication to quality and innovation will play a crucial role in increasing patient access to this advanced technology across Europe.”

About Altrazeal^® (Transforming Powder Dressing™)
Altrazeal^® is a patented, amorphous dressing comprising primarily of methacrylate-based polymers similar to those used in contact lenses. Upon hydration, its granules aggregate to form a moist, oxygen permeable matrix that conforms to the wound bed. The matrix protects the wound from exogenous bacteria while allowing excess exudate to flow through it via vapor transpiration to create an optimal environment for wound healing. As the wound heals, the Altrazeal^® matrix dries and flakes off.

Altrazeal^® enables extended wear time of up to 30 days, allowing the wound to heal without disturbing the wound bed with frequent dressing changes. It is particularly effective in the management of complex, painful, and difficult-to-dress wounds where recurrent dressing changes can aggravate pain and increase wound exposure to contamination.

For more information about Altrazeal^®, please visit https://altrazeal.com

Sources

1. [1] List of Altrazeal® clinical trials (available at www.altrazeal.com)

1. • Atypical Wounds (https://altrazeal.com/atypical-2/)

1. • Burns (https://altrazeal.com/burns/)

1. • Colorectal (https://altrazeal.com/colorectal/)

1. • Diabetic Foot Ulcers (https://altrazeal.com/diabetic-foot-ulcers/)

1. • Pediatric (https://altrazeal.com/pediatric/)

1. • Pressure Injuries (https://altrazeal.com/pressure-injuries/#NOPE)

1. • Skin Graft Donor and Recipient Sites (https://altrazeal.com/skin-graft-donor-and-recipient-sites/)

1. • Surgical (https://altrazeal.com/surgical/)

1. • Trauma (https://altrazeal.com/trauma/)

1. • Vascular Ulcers (https://altrazeal.com/vascular-ulcers/)

Athens, October 17, 2025 – INTEGRIS Pharma S.A., a pharmaceutical company based in Athens, Greece, dedicated to ensuring timely patient access to innovative therapies in Oncology, Hematology and Rare Diseases, today announced the exclusive collaboration agreement with Citius Oncology, Inc. (Nasdaq: CTOR) to support patients with relapsed or refractory Cutaneous T-Cell Lymphoma (CTCL), in Southern Europe.

The agreement covers 12 countries: Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia and Herzegovina, Kosovo, Montenegro, and North Macedonia. Through this collaboration, patients with relapsed or refractory CTCL will gain access to an FDA-approved innovative therapy.

Referring to the collaboration, Dr. Charalampos Therianos, CEO of INTEGRIS Pharma, stated:
“Our collaboration with Citius Oncology represents an important milestone in our mission to bring innovative therapies closer to patients with rare, chronic and life-threatening diseases. Based on our expertise, our close collaboration with Regulatory Authorities and Hospitals, our firm commitment to regulatory compliance, and with a focus on patient support, INTEGRIS Pharma is ready to ensure that patients with relapsed or refractory Cutaneous T-Cell Lymphoma (CTCL) will have access to new therapeutic options when they need them.”

The CEO of Citius Oncology and Citius Pharmaceuticals, Leonard Mazur, stated:
“The expansion of access to international markets represents for Citius Oncology a patient-centered mission as well as a strategic opportunity. Through our recent exclusive agreement with INTEGRIS Pharma, we are given the opportunity to serve more patients with Cutaneous T-Cell Lymphoma (CTCL) who need access to new therapeutic options, while at the same time establishing a reliable collaboration for us in Southern Europe.”

About Cutaneous T-cell Lymphoma (CTCL)

Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that plays a role in the immune system, become cancerous and develop into skin lesions, leading to a decrease in the quality of life of patients with this disease due to severe pain and pruritus. Mycosis Fungoides (MF) and Sézary Syndrome (SS) comprise the majority of CTCL cases.

Depending on the type of CTCL, the disease may progress slowly and can take anywhere from several years to upwards of ten to potentially reach tumor stage. However, once the disease reaches this stage, the cancer is highly malignant and can spread to the lymph nodes and internal organs, resulting in a poor prognosis. Given the duration of the disease, patients typically cycle through multiple agents to control disease progression. CTCL affects men twice as often as women and is typically first diagnosed in patients between the ages of 50 and 60 years of age. Other than allogeneic stem cell transplantation, for which only a small fraction of patients qualify there is currently no curative therapy for advanced CTCL.

About Citius Oncology, Inc.

Citius Oncology is a specialty biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies.
The company holds robust intellectual property protections that span orphan drug designation, complex technology, trade secrets, and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors, that would further support Citius Oncology’s  competitive positioning.
Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals.